Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anle138b

            Therapeutic Area: Neurology Product Name: Anle138b

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson's Research.

            Deal Size: $1.4 million Upfront Cash: Undisclosed

            Deal Type: Funding August 05, 2020

            Details:

            Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models.